Cardiology

Back to articles

Recent study finds dapagliflozin improves heart failure outcomes regardless of diabetes status

KEY POINT

Use of dapagliflozin (Farxiga—AstraZeneca) in patients with heart failure (HF) and a reduced ejection fraction (EF) decreased the risk of worsening HF or cardiovascular (CV) death regardless of the patient’s diabetes status, according to a study published in the New England Journal of Medicine.

SOURCES

McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;[Epub ahead of print].

Fang JC, et al. Heart-failure therapy–new drugs but old habits? N Engl J Med. 2019;[Epub ahead of print].